Anti Neurocan (NCAN) mAb (Clone 1G2)

Antibodies/Primary Antibodies/Cell Adhesion & Migration; Research Area/Development/Brain & CNS/Primary Antibodies; Research Area/Cell Biology/Cell Adhesion & Migration/Primary Antibodies; Antibodies/Abs For Paraffin Embedded Tissue/Cell Adhesion & Migration; Research Area/Cell Biology/Cell Adhesion & Migration/Abs For Paraffin Embedded Tissue; Research Area/Development/Brain & CNS/Abs For Paraffin Embedded Tissue; Glycobiology/Abs For Paraffin Embedded Tissue/Proteoglycans; Glycobiology/Primary Antibodies/Proteoglycans; Glycobiology/Proteoglycans/Abs For Paraffin Embedded Tissue; Glycobiology/Proteoglycans/Primary Antibodies; Antibodies/Cell Adhesion & Migration/Abs For Paraffin Embedded Tissue; Antibodies/Cell Adhesion & Migration/Primary Antibodies; Research Area/Development/Skeletal System/Primary Antibodies; Research Area/Development/Skeletal System/Abs For Paraffin Embedded Tissue; Research Area/Glycobiology/Proteoglycans/Abs For Paraffin Embedded Tissue; Research Area/Glycobiology/Proteoglycans/Primary Antibodies

Neurocan is a nervous tissue-unique, secretory proteoglycan that carries predominantly chondroitin sulfate side chains. Its expression gradually decreases with nervous tissue development. In the immature brain, neurocan exists in a full-length form with a 240 kDa-core glycoprotein, whereas in the mature brain it exists as proteolytic fragments of the NH2-terminal half (neurocan-N) with a 130 kDa-core glycopeptide and the COOH-terminal half (neurocan-C) with a 150 kDa-core glycopeptide. Neurocan is implicated in neural network formation and is a susceptibility factor for bipolar disorder. It is upregulated in central nervous system lesion sites and is a major component of glial scars. This antibody effectively recognizes the COOH-terminal half of rat neurocan core glycoprotein as well as the full length neurocan core glycoprotein.
References:
1) Oohira, A. et al. (1994) Neuroscience. 60:145-157. PMID: 8052408.
2) Matsui, F. et al. (1994) Neurochem. Int. 25:425-431.
3) Watanabe, E. et al. (1995) Eur. J. Neurosci. 7:547-554.
4) Fukuda, T. et al. (1997) J. Comp. Neurol. 382:141-152.
5) Inatani, M. et al. (1999) Invest. Ophthalmol. Vis. Sci. 40:2350-2359.

Monoclonal